

Fig.1




Fig.2

FIG.2A




FIG.2B




Fig.3

FIG.3A




FIG.3B




FIG.3C





Fig. 4





Fig.5






**FIG.6A**




**FIG.6B**

P1AD4470: CD40 IgG1  
P1AE2423: CD40 x FAP (212) 2+1 crossfab  
P1AE2487: CD40 x FAP (4B9) 2+1 crossfab  
P1AE2302: CD40 x FAP (28H1) 2+1 crossfab  
P1AE2424: CD40 x FAP (212) 4+1 crossfab  
P1AE2895: CD40 x FAP (4B9) 4+1 crossfab  
P1AE2024: CD40 x FAP (28H1) 4+1 crossfab

Fig. 7




FIG.7A




FIG.7B

P1AD4470: CD40 IgG1  
P1AE2423: CD40 x FAP (212) 2+1 crossfab  
P1AE2487: CD40 x FAP (4B9) 2+1 crossfab  
P1AE2302: CD40 x FAP (28H1) 2+1 crossfab  
P1AE2424: CD40 x FAP (212) 4+1 crossfab  
P1AE2895: CD40 x FAP (4B9) 4+1 crossfab  
P1AE2024: CD40 x FAP (28H1) 4+1 crossfab

Fig.8






Fig.9



10/19

Fig.10





Fig.11



12/19





Fig. 12

13/19

Fig.13A



14/19

Fig.13B




Fig.14




Fig.15




FIG.15A

FIG.15B

FIG.15C

FIG.15D

Fig.16

CD8 T cell activation (d4)




FIG.16A


FIG.16B

FIG.16C

FIG.16D

Fig.17

B cell activation (d4)



tumors of mice treated with the 4+1 antibody were too small to obtain reliable results

FIG.17A

FIG.17B

FIG.17C

FIG.17D

Fig. 18

